DGAP-News 552 0 Kommentare EVOTEC AND MARS INNOVATION ESTABLISH STRATEGIC PARTNERSHIP TO LAUNCH FIBROCOR THERAPEUTICS - Seite 2

The company's core focus will be to develop novel therapeutics that have
the potential to prevent, slow and ultimately reverse the course of
fibrosis. Fibrocor has already identified a lead programme and will partner
with Evotec to develop novel molecules with the anticipation of nominating
a lead candidate in 2018. In addition, Fibrocor will collaborate with its
academic co-founders to expand access to tissue samples to include several
relevant tissues, such as lung, liver, kidney, colon and skin. Fibrocor
will seek to identify novel targets and molecular pathways that are
identified from and validated in clinical samples from individuals with the
targeted disease for follow-on drug discovery and development programmes in
fibrosis, generating a robust pipeline of novel therapeutic targets that it
will subsequently work with Evotec on.

"Fibrosis continues to be an area of huge unmet medical need. Combining
Fibrocor's ability to identify novel disease relevant targets and Evotec's
industry-leading drug discovery platform should greatly increase the
probability of delivering effective medicines for patients. We are
delighted to be a part of the launch of Fibrocor together with MaRS
Innovation and look forward to working with our new partners in this
exciting venture", said Dr Mario Polywka, Chief Operating Officer of
Evotec.

ABOUT FIBROCOR THERAPEUTICS

Fibrocor Therapeutics is focused on developing disease modifying
therapeutics in fibrosis. The company's platform is based on discovery of
novel targets and dissection of molecular pathways from a well annotated
tissue bank of diseased and non-diseased patient samples. As one of the
first platforms that discover targets directly from human samples, the
company was founded based on the transformational work of Drs. Richard
Gilbert and Darren Yuen at St. Michael Hospital and Dr Jeff Wrana at Mount
Sinai Hospital all of whom are cross appointed to the University of
Toronto. Using this first-in class tissue discovery platform, Fibrocor has
partnered with Evotec to develop first-in class therapeutics to novel
molecular targets and pathways in fibrosis.